公司产品和市场 - 公司是一家专注于心血管健康和降低心血管风险的制药公司[226] - VASCEPA是公司的商业化产品，已在美国获得批准，并在欧洲获得市场授权[226] - 在2020年，VASCEPA的总处方量超过了2000万[227] - 公司已在欧洲的多个国家获得了VAZKEPA的市场准入，并计划在欧洲主要市场推出VAZKEPA[232] - 公司与Eddingpharm合作，在中国领土开发和商业化VASCEPA胶囊[232] - 公司与Biologix合作，在中东和北非地区注册和商业化VASCEPA[233] - REDUCE-IT研究结果显示，VASCEPA在患有冠心病患者中降低心血管死亡、中风、心肌梗死、冠状动脉重建和不稳定性心绞痛的风险[242] - 2022年，公司与CSL Seqirus达成协议，在澳大利亚和新西兰定价、报销、商业化和分销VAZKEPA[236] - 2022年，公司宣布启动了一种固定剂量组合产品的开发，其中含有icosapent ethyl和一种他汀类药物[246] - 美国市场的VASCEPA销售量和净销售价格下降，主要受到市场中仿制药竞争的影响[259] 公司财务状况 - 公司在2022年实施了全面的成本和组织重组计划，预计将在未来12个月内节省1亿美元[228] - 2022年和2021年，公司总净收入分别为3.692亿美元和5.832亿美元，下降了37%[259] - 2022年和2021年，产品净收入分别为3.665亿美元和5.803亿美元，下降了37%[259] - 2022年度许可和版税收入为2.7百万美元，较2021年度的2.9百万美元减少了0.2百万美元，降幅为6%[261] - 2022年度销售成本为1.267亿美元，较2021年度的1.213亿美元增加了0.54亿美元，增幅为4%[262] - 2022年度产品销售毛利率为65%，较2021年度的79%下降，不计入重组存货和库存冲销的情况下，毛利率为73%[263] - 2022年度销售、一般和行政费用为3.044亿美元，较2021年度的4.083亿美元减少了1.039亿美元，降幅为25%[263] - 2022年度研发费用为3.04百万美元，较2021年度的2.93百万美元增加了1.1百万美元，增幅为4%[268] - 截至2022年12月31日，公司的总流动资金约为3.112亿美元，无债务[273] - 2022年度净利息收入为2.8百万美元，较2021年度的1.1百万美元增加了1.7百万美元，增幅为157%[272] - 2022年度其他（费用）收入为0.7百万美元，较2021年度的0.3百万美元增加了0.4百万美元[272] - 2022年度所得税费用为2.0百万美元，较2021年度的3.6百万美元减少了1.6百万美元[272] - 截至2022年12月31日，公司的现金及现金等价物为2.177亿美元，短期投资为0.917亿美元[274] - 公司不使用衍生金融工具进行投资，也不进行外汇合约[276] - 大部分现金及现金等价物、投资和大部分供应商关系以美元计价，因此认为外汇波动对经营收入的影响不大[276] - 公司的投资组合主要由美国国债、商业票据、公司债券、CD和资产支持证券等组成，投资组合平衡多样化，利息率变动10%不会对证券公允价值产生重大影响[278]

Amarin Corporation plc (NASDAQ:AMRN) SVB Securities Global Biopharma Conference February 14, 2023 10:40 AM ET Company Participants Karim Mikhail - President & CEO Tom Reilly - Chief Financial Officer Conference Call Participants Roanna Ruiz - SVB Securities Roanna Ruiz Great. Welcome back, everyone. I'm Roanna Ruiz, Senior Biotech Analyst here at SVB Securities, and it's my pleasure to introduce members of the Amarin management team, specifically, Karim Mikhail, President and CEO and Tom Reilly, CFO. So wel ...

SVB Securities Global Biopharma Conference Karim Mikhail President & CEO February 14, 2023 Forward Looking Statements & Disclaimer This presentation contains forward-looking statements which are made pursuant to U.S. federal securities law, including beliefs about Amarin's key achievements in 2022 and the potential impact and outlook for achievements in 2023 and beyond; Amarin's 2023 financial outlook and cash position; strategies to ensure profit maximization; Amarin's strategic direction and actions manag ...

41st Annual J.P. Morgan Healthcare Conference Karim Mikhail President & CEO January 23 Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, patent litigation, generic product launch, intellectual property, cash flow, research and development, and other statements that are forward-looking in na ...

Amarin Corporation plc (NASDAQ:AMRN) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 8:15 PM ET Company Participants Karim Mikhail - President and Chief Executive Officer Tom Reilly - Chief Financial Officer [Call Starts Abruptly] -- in Europe. And the Board took upon itself to refresh itself also. So, they have initiated a process, in October, of 2021. And for now, we basically have 75% of new board members. So, you see on the list here all the new board members who were added to the list wh ...

Amarin Corporation plc (NASDAQ:AMRN) 13th Annual Jefferies London Healthcare Conference 2022 November 16, 2022 9:40 AM ET Company Participants Karim Mikhail - President and Chief Executive Officer Tom Reilly - Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Michael Yee Well, we'll get stared. Hey, it's Michael Yee here, senior biotechnology analyst at Jefferies. Very happy to have the team from Amarin. Up here with us to give a brief presentation, we have the CEO, Karim Mikhail ...

Amarin Corporation plc (NASDAQ:AMRN) Q3 2022 Results Earnings Conference Call October 27, 2022 8:00 AM ET Company Participants Lisa DeFrancesco - Senior Vice President, Corporate Affairs and Investor Relations Karim Mikhail - President and Chief Executive Officer Tom Reilly - Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Georgi Yordanov - Cowen and Company Roanna Ruiz - SVB Leerink Carvey Leung - Cantor Fitzgerald Daniel Wolle - J.P. Morgan Paul Choi - Goldman Sachs Operator W ...

Amarin Corporation Plc (NASDAQ:AMRN) H.C. Wainwright Global Investment Conference September 12, 2022 9:00 AM ET Company Participants Karim Mikhail - President, CEO & Director Thomas Reilly - CFO & SVP Conference Call Participants Andrew Fein - H.C. Wainwright & Co. Andrew Fein Hello, everyone. I'm Andrew Fein, one of the biotechnology analysts at H.C. Wainwright. Thank you for coming. Glad to be back in person. So the next company presenting will be Amarin, and presenting for the company will be its Presid ...